Edwards Lifesciences Corporation $EW Shares Sold by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio reduced its holdings in Edwards Lifesciences Corporation by 3.1%, owning 240,089 shares valued at $18.78 million after selling 7,609 shares.
• Edwards Lifesciences reported an EPS of $0.67 for Q2, surpassing analysts' estimates, with revenue increasing 11.9% year-over-year to $1.53 billion.
• Analyst ratings for Edwards Lifesciences show a consensus rating of Moderate Buy with a target price of $86.61, indicating positive growth expectations.

Public Employees Retirement System of Ohio decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 240,089 shares of the medical research company's stock after selling 7,609 shares during the period. Public Employees Retirement System of Ohio's holdings in Edwards Lifesciences were worth $18,777,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the 1st quarter worth $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $27,000. Rossby Financial LCC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $29,000. Costello Asset Management INC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth $29,000. Finally, Global X Japan Co. Ltd. increased its holdings in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.9%

Shares of NYSE:EW opened at $75.35 on Friday. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The stock has a 50-day simple moving average of $78.50 and a 200-day simple moving average of $75.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market capitalization of $44.24 billion, a P/E ratio of 10.84, a PEG ratio of 3.59 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.70 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EW shares. Truist Financial increased their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Robert W. Baird increased their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Finally, Evercore ISI increased their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $86.61.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.